Work

Supplementary Figure 2 from A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma

Year: 2023

Type: supplementary-materials

Abstract: Kaplan-Meier curve of duration of response among 9 responders on the study, measured from the date of response (as compared with baseline) till progression or censorship when patient follow-up ended. Median time to progression was not reached. Hatch marks denote time that patients are censored.

DOI: 10.1158/1078-0432.22471605

Authors: Ramya Ramaswami, Thomas S. Uldrick, Mark N. Polizzotto, Kathleen M. Wyvill, Priscila Goncalves, Anaida Widell, Kathryn Lurain, Seth M. Steinberg, William Douglas Figg, Giovanna Tosato, Denise Whitby, Robert Yarchoan

Language: English

Topic: Viral-associated cancers and disorders

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362406591

Cites:

Cited by:

Related to: 10